PD-1 monoanti-Opdivo combined with TKI inhibitor Cabometyx to treat kidney cancer, which received FDA priority review.

The latest data show that a combination of Bristol Myers Squibb and Exelixis' Opdivo and Tyrosine Kinase Inhibitor (TKI) Cabometyx can extend the survival of patients with kidney cancer.
according to CheckMate 9ER data reported a month ago by the European Society of Medical Oncology (ESMO), the combination of Opdivo and Cabometyx reduced the risk of death by 40 per cent compared to Pfizer's Sunitinib, sutent, after a median 18-month follow-up.
and Pfizer's Keytruda and Inlyta, which also used a combination of PD-1 inhibitors and TKI, followed the Keynote-426 trial for 17 months and showed a 41 percent lower risk of death than Sutt.
and the duration of the reaction was very similar, with Opdivo-Cabometyx responding at 20.2 months and Keytruda-Inlyta at 20.9 months.
Graybosch, an analyst at SVB Leerink, said Keytruda's strong position in checkpoint inhibitors could give Merck the upper hand.
But in terms of TKI competition, Exelixis' Cabometyx, which is approved as a single-drug treatment for untreated kidney cancer patients, appears to have an advantage over Pfizer's Inlyta, which has only been approved for second-line treatment.
.